A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Deal with lunesta





ALSO NOTED ImaRx prices IPO Sepracor, Eisai sign deal for Lunesta

12/17/2014
02:51 | Author: Christina Harris

Stop taking paxil
ALSO NOTED ImaRx prices IPO Sepracor, Eisai sign deal for Lunesta

Sepracor and Eisai have signed a deal development and commercialization of Sepracor's sleep drug Lunesta for the Japanese market.

Comments (0)



End of Sepracor-GSK Deal Raises Question in Lunesta Patent Fight

12/17/2014
10:38 | Author: Evan Martin

Deal with lunesta
End of Sepracor-GSK Deal Raises Question in Lunesta Patent Fight

Here's something that few noticed in Sepracor's Q1 2009 earnings announcement: The company's $155 million marketing deal for insomnia.

Quotes delayed at least 15 minutes. Market data provided by Interactive Data. Terms & Conditions.

Stream CBSN live or on demand for FREE on your TV, computer, tablet, or smartphone. Watch CBS News anytime, anywhere with the new 24/7 digital news network.

Company fundamental data provided by Zacks.

Some of these careers are not all they're cracked up to be, while others have serious potential.

Powered and implemented by Interactive Data Managed Solutions News provided by The Associated Press.

Last Updated Jun 13, 2009 6:51 PM EDT.

2014 CBS Interactive Inc.

The warehouse retailer is a tightly run operation that knows exactly how to make money in good times and bad.

Comments (0)

Best deal on Lunesta Best prices ever - Quark Forums

12/17/2014
08:07 | Author: Kate Thompson

Stop taking paxil
Best deal on Lunesta Best prices ever - Quark Forums

Click here to order Lunesta + The most trusted online drug supplier + High Quality Lunesta Only + Cheap Lunesta online is guaranteed aderal · metronidazole.

Comments (0)

GlaxoSmithKline, Sepracor in marketing deal for Lunesta - FirstWord

12/17/2014
06:44 | Author: Devin Garcia

Deal with lunesta
GlaxoSmithKline, Sepracor in marketing deal for Lunesta - FirstWord

GlaxoSmithKline and Sepracor entered into an agreement whereby GlaxoSmithKline will market Sepracor's sleep disorder drug, Lunesta.

Kelly anticipates that if approved, the drug could see peak annual sales of $300 million in the EU.

The insomnia drug, which had sales of $566.8 million in 2006, is currently under review by EU regulators, and a decision is expected by the second half of next year. The analyst added that "Sepracor and GlaxoSmithKline expect that the six-month treatment data could offer an opportunity for long-term use as a claim that will differentiate and provide reimbursement opportunities.". "Lunivia will need to differentiate itself from generics, especially in cost-conscious Europe, where hypnotics face generic competition and the market is approximay $500 million," noted Goldman Sach's James Kelly.

GlaxoSmithKline will also pay Sepracor compensation for the supply of the drug, as well as royalties on product sales. Sepracor's CEO, Adrian Adams, remarked that the deal is "another important step in Sepracor’s overall worldwide strategy to fully leverage our product franchises.”. Under the terms of the deal announced Tuesday, Sepracor will be eligible for up to $155 million in licence and milestone payments.

GlaxoSmithKline expects to commercialise the treatment as Lunivia. GlaxoSmithKline and Sepracor entered into an agreement whereby GlaxoSmithKline will market Sepracor's sleep disorder drug, Lunesta (eszopiclone) on a global basis, excluding the US, Canada, Mexico and Japan.

To read more Top Story articles, click here.

Comments (0)

Lupin Strikes Deal In Suit Over Generic Lunesta - Law360

12/17/2014
04:15 | Author: Kate Thompson

Deal with lunesta
Lupin Strikes Deal In Suit Over Generic Lunesta - Law360

Lupin Strikes Deal In Suit Over Generic Lunesta. By Evan Weinberger. Law360, New York (January 03, 2011, 4:11 PM ET) -- Lupin Ltd. on Monday announced.

(Professional required) First Name Last Name.

By Evan Weinberger. Make sure you don't miss any Law360 breaking news.

Already a subscriber? Click here to login.

Password (at least 6 characters required) Confirm Password.

Comments (0)